Dendritic Cell Cancer Vaccine

Dendritic Cell Cancer Vaccine Market Outlook

The global dendritic cell cancer vaccine market is projected to reach USD 5.8 billion by 2035, growing at a CAGR of 10.3% from 2025 to 2035. The growth of this market is attributed to the rising incidence of cancer globally, increased investment in cancer research, and advancements in personalized medicine which have led to the development of more effective therapeutic options. With a growing awareness about the efficacy of dendritic cell vaccines in stimulating immune response against tumors, healthcare providers are increasingly integrating these vaccines into treatment protocols, further propelling market growth. Additionally, supportive government regulations and funding for cancer research initiatives are expected to foster innovation and expansion in this field. Overall, the dendritic cell cancer vaccine market is anticipated to experience significant growth as a result of these dynamic factors.

Growth Factor of the Market

The dendritic cell cancer vaccine market is experiencing a notable surge in growth due to a combination of factors such as advancements in immunotherapy and the increasing prevalence of various types of cancer. The growing understanding of the role of dendritic cells in the immune system has led to innovative therapeutic strategies that harness these cells for cancer treatment. Furthermore, the increasing number of clinical trials and research studies focusing on dendritic cell vaccines has catalyzed interest across the pharmaceutical and biotechnology sectors. This is complemented by technological advancements in cell culture and vaccine formulation processes that enhance the efficacy and specificity of treatments. Additionally, the market is positively influenced by rising healthcare expenditures, which have globally increased due to a heightened focus on personalized medicine and targeted therapies, making dendritic cell vaccines a pivotal component in modern oncology treatment.

Key Highlights of the Market

• Significant rise in the incidence of cancer globally driving demand for effective vaccines.
• Advancements in dendritic cell vaccine technology enhancing efficacy and patient outcomes.
• Increasing government funding and support for cancer research initiatives globally.
• Growing awareness among healthcare professionals regarding personalized medicine.
• Emergence of new players and innovative products enhancing market competition.

By Product Type

Autologous Dendritic Cell Cancer Vaccine:

Autologous dendritic cell cancer vaccines are derived from a patient’s own dendritic cells, which are harvested and modified to present tumor antigens. This type of vaccine has gained traction in personalized medicine because it minimizes the risk of adverse reactions and enhances the body’s immune response against cancer cells. The production process, however, is complex and time-consuming, which can limit its widespread adoption. Nonetheless, the customized nature of autologous vaccines has shown promising results in clinical trials, particularly for melanoma and prostate cancer, leading to a strong preference among oncologists for utilizing autologous approaches in therapy. The growing body of evidence supporting the efficacy and safety of these vaccines continues to drive market growth as more patients seek individualized treatment options.

Allogeneic Dendritic Cell Cancer Vaccine:

Allogeneic dendritic cell cancer vaccines utilize dendritic cells from healthy donors rather than the patient’s own cells. This type of vaccine offers several advantages, including a more straightforward production process and the potential for immediate availability for multiple patients. Allogeneic vaccines can target a broader range of tumors, making them an appealing option for patients who may not have sufficient viable cells for autologous vaccine production. The growing investment in research and development of allogeneic dendritic cell vaccines has led to the exploration of combinatory therapies, which aim to enhance the overall efficacy by integrating these vaccines with other treatment modalities such as checkpoint inhibitors. As clinical trials demonstrate the potential of allogeneic vaccines to improve patient outcomes, they are expected to gain substantial market share in the coming years.

By Application

Melanoma:

Melanoma, a type of skin cancer, is one of the leading applications for dendritic cell cancer vaccines. The complexity and aggressiveness of melanoma make it a suitable target for immunotherapy, particularly dendritic cell-based strategies. The use of dendritic cell vaccines in melanoma treatment has shown promising outcomes, as these vaccines can train the immune system to recognize and destroy melanoma cells effectively. With increasing incidence rates of melanoma globally, there is a heightened demand for innovative treatment options, driving research and development efforts in this area. Moreover, ongoing clinical trials are examining the efficacy of dendritic cell vaccines in combination with other immunotherapies, further propelling their adoption in melanoma treatment protocols.

Prostate Cancer:

Prostate cancer represents a significant application for dendritic cell cancer vaccines, particularly due to the need for effective therapeutic strategies for advanced stages of the disease. Dendritic cell vaccines have shown favorable results in enhancing immune responses against prostate cancer cells, leading to prolonged survival rates for patients. The ability of these vaccines to be tailored to individual patients has made them a particularly attractive option in prostate cancer treatment. As the prevalence of prostate cancer continues to rise, fueled by aging populations and improved diagnostic techniques, the market for dendritic cell vaccines specifically targeting this application is expected to grow, supported by ongoing clinical studies and increasing acceptance among urologists and oncologists.

Breast Cancer:

Breast cancer is another key application area for dendritic cell cancer vaccines, as researchers are actively exploring their potential to enhance the immune response against this prevalent malignancy. Dendritic cell vaccines have demonstrated the ability to induce specific T-cell responses against breast cancer antigens, which could lead to improved patient outcomes. The shift toward personalized medicine has further intensified interest in using dendritic cells for breast cancer therapy, especially in cases resistant to conventional treatments. With the rising incidence of breast cancer globally, there is a growing impetus for the development and clinical implementation of dendritic cell vaccines, supported by ongoing research and collaboration between academic institutions and biotechnology companies.

Lung Cancer:

The application of dendritic cell cancer vaccines in lung cancer is gaining momentum due to the urgent need for innovative therapies to combat this leading cause of cancer-related mortality. Dendritic cell vaccines have been shown to stimulate robust immune responses against lung cancer cells, potentially improving survival outcomes in patients. The complexity of lung cancer, which often presents in advanced stages, necessitates the development of novel treatment strategies that can be integrated with existing therapies, such as chemotherapy and radiation. As clinical trials continue to yield positive results, dendritic cell vaccines are anticipated to play a critical role in shaping the future landscape of lung cancer treatment—providing new hope for patients and oncologists alike.

Others:

In addition to melanoma, prostate, breast, and lung cancer, dendritic cell vaccines are being investigated for their efficacy in treating other malignancies, including ovarian cancer, bladder cancer, and head and neck cancers. The versatility of dendritic cell-based immunotherapy allows for the exploration of various tumor antigens, making it applicable across a wide range of cancer types. As researchers continue to expand the understanding of the immune system's interactions with different cancers, the development of dendritic cell vaccines tailored for other cancer types is expected to gain traction. This growing interest in diversified applications is likely to contribute positively to the overall growth of the dendritic cell cancer vaccine market as new products emerge to meet the needs of different patient populations.

By Distribution Channel

Hospitals:

Hospitals are a primary distribution channel for dendritic cell cancer vaccines, serving as the main site for patient treatment and monitoring. The integration of dendritic cell vaccines into hospital oncology departments provides patients with access to advanced immunotherapy options. Hospitals typically have the infrastructure necessary for the complex production and administration of these vaccines, which is critical given the personalized nature of autologous vaccines. Furthermore, the collaboration between hospitals and research institutions facilitates clinical trials, fostering innovation. As hospitals continue to adopt cutting-edge treatments for cancer, their role in distributing dendritic cell vaccines will remain vital in the overall market landscape.

Cancer Research Centers:

Cancer research centers are crucial distribution channels for dendritic cell cancer vaccines as they are often at the forefront of clinical trials and pioneering research. These specialized facilities conduct extensive studies to evaluate the efficacy and safety of dendritic cell vaccines, providing valuable data that influences market trends. Moreover, research centers often collaborate with pharmaceutical companies to develop and manufacture vaccines, ensuring that innovative therapies are brought to market efficiently. As interest in immunotherapy grows and more research centers focus on dendritic cell-based approaches, their significance in the distribution of these vaccines is expected to increase, thereby shaping the future of cancer treatment.

Specialty Clinics:

Specialty clinics play an important role in the distribution of dendritic cell cancer vaccines, primarily as they cater to patients seeking alternative or complementary therapies. These clinics often focus on personalized medicine and may offer dendritic cell vaccines in conjunction with other holistic approaches to cancer treatment. The flexibility and tailored nature of dendritic cell vaccines align well with the philosophies of specialty clinics, making them a popular choice among patients who are looking for innovative options. As more clinics adopt these therapies, the accessibility of dendritic cell vaccines is expected to expand, attracting a wider patient demographic seeking cutting-edge cancer treatment.

Others:

Other distribution channels for dendritic cell cancer vaccines include academic institutions and collaborative partnerships with biotechnology firms. These channels often focus on research and development aspects, aiding in the discovery and refinement of new vaccine formulations. As collaboration between academia and industry continues to thrive, innovative dendritic cell vaccine products are likely to emerge from these partnerships, enhancing the overall distribution landscape. Additionally, online platforms may also begin offering consultation and information about dendritic cell vaccines as awareness and education regarding immunotherapy options increase among patients and healthcare providers alike.

By Ingredient Type

Dendritic Cells:

Dendritic cells are the primary ingredient in dendritic cell cancer vaccines, acting as key modulators of the immune response. These specialized immune cells are responsible for processing and presenting antigens to T-cells, thereby activating the immune system to target and eliminate cancer cells. The extraction and manipulation of dendritic cells from patient samples are critical processes that determine the effectiveness of the vaccine. Advances in cell culture techniques and quality control measures are essential to ensure the viability and functionality of dendritic cells in therapeutic applications. As research continues to optimize dendritic cell production, this segment of the ingredient market is poised for significant growth, contributing to the overall expansion of dendritic cell cancer vaccines.

Tumor Antigens:

Tumor antigens, which are derived from cancer cells, serve as the targets for dendritic cell vaccines. The identification and selection of appropriate tumor antigens are crucial for eliciting a robust immune response. Various research studies focus on discovering novel tumor antigens that can enhance the specificity and effectiveness of dendritic cell vaccines. As advances in genomics and proteomics technologies emerge, the ability to personalize tumor antigen selection is likely to improve, leading to more effective treatment options for patients. The increasing understanding of tumor immunology will further drive the demand for innovative tumor antigen-based vaccines, making this ingredient segment a vital component of the dendritic cell cancer vaccine market.

Adjuvants:

Adjuvants are substances that enhance the body’s immune response to specific antigens, playing a crucial role in dendritic cell cancer vaccines. By incorporating adjuvants into vaccine formulations, researchers aim to boost the effectiveness of dendritic cell activation, leading to a more pronounced antitumor response. The development of novel adjuvants, including those derived from natural sources and synthetic compounds, continues to be a key focus in the field of immunotherapy. As the market for dendritic cell vaccines expands, the incorporation of adjuvants that improve vaccine efficacy and patient outcomes will be increasingly emphasized, contributing to advancements in cancer treatment strategies.

Others:

Other ingredient types in dendritic cell cancer vaccines may include various immune-modulating agents and excipients that facilitate vaccine formulation and delivery. These ingredients play supplementary roles in enhancing the stability and bioavailability of the vaccine, ensuring that the active components can effectively stimulate the immune system. The exploration of alternative ingredients and formulation techniques is expected to grow, driven by a commitment to improving vaccine performance and patient adherence. As research continues to uncover new possibilities in dendritic cell vaccine formulations, the diversity of ingredients will likely expand, enriching the overall market landscape and providing patients with a greater range of therapeutic options.

By Region

The dendritic cell cancer vaccine market is witnessing significant growth across various regions, with North America holding the largest share due to its advanced healthcare infrastructure and robust investment in cancer research. In 2025, North America is projected to account for approximately 45% of the global market, driven by the presence of leading pharmaceutical companies, research institutions, and a high prevalence of cancer. The region also benefits from favorable reimbursement policies for innovative therapies and a growing interest in personalized medicine, further propelling the market forward. Moreover, an increasing number of clinical trials conducted in North America will contribute to the validation and adoption of dendritic cell vaccines, making it a critical hub for market activity.

Europe is another important region in the dendritic cell cancer vaccine market, expected to capture a significant market share by 2025, accounting for around 30% of the total revenue. The European market is characterized by strong collaboration between academic institutions and biotechnology firms, fostering innovation and research in dendritic cell therapy. Countries such as Germany, France, and the United Kingdom are leading the charge in clinical research, with several prominent cancer centers actively exploring dendritic cell vaccines in their treatment protocols. Moreover, the European Medicines Agency (EMA) has been supportive of advanced therapies, which will likely enhance the market’s growth trajectory in this region. The cumulative annual growth rate (CAGR) for Europe is anticipated to be approximately 9.5% during the forecast period, as regulatory approvals and increasing patient awareness create further momentum for dendritic cell cancer vaccines.

Opportunities

The dendritic cell cancer vaccine market is teeming with opportunities, particularly due to the increasing global focus on personalized medicine. Patients and healthcare professionals are shifting their preferences towards tailored therapies that consider individual patient characteristics, which has led to the rise of dendritic cell vaccines as a viable option. Additionally, as research continues to uncover new tumor antigens and adjuvants, the potential for developing more effective vaccines expands, thereby attracting investment from pharmaceutical and biotechnology companies. Collaborative efforts between research institutions and industry players are resulting in innovative clinical trials, which not only enhance the credibility of dendritic cell vaccines but also provide opportunities for gaining regulatory approvals. Furthermore, as awareness grows about the benefits of immunotherapy, more patients are likely to seek out dendritic cell vaccines, creating a burgeoning demand in the market.

Moreover, the trend towards combination therapies presents additional opportunities for the dendritic cell cancer vaccine market. By integrating dendritic cell vaccines with other treatment modalities such as checkpoint inhibitors and monoclonal antibodies, researchers can create synergistic effects that amplify therapeutic efficacy. This approach has the potential to improve patient outcomes significantly, encouraging the development of combination clinical trials and increasing market interest. As more healthcare providers recognize the value of a multi-faceted approach to cancer treatment, the incorporation of dendritic cell vaccines into comprehensive therapies is likely to gain traction, further positioning them as a central component of future oncology treatment protocols.

Threats

Despite the promising outlook for the dendritic cell cancer vaccine market, several threats could hinder its growth trajectory. One major concern is the high cost associated with the production and administration of dendritic cell vaccines, which may limit accessibility for patients and healthcare providers. The intricate manufacturing processes required for these personalized therapies can lead to significant price points, creating barriers for reimbursement and insurance coverage. Additionally, the complexity of clinical trial designs for dendritic cell vaccines, which often require extensive patient monitoring and long follow-up periods, may pose challenges in terms of time and cost. Such hurdles could deter potential investors and slow down the pace of innovation in the market.

Another potential threat is the competitive landscape, as numerous companies are actively pursuing the development of dendritic cell vaccines and other forms of immunotherapy. This intense competition may result in market saturation, making it difficult for new entrants to secure a foothold. Furthermore, the rapid evolution of cancer treatment paradigms, with the introduction of novel therapies and technologies, could overshadow the potential benefits of dendritic cell vaccines. As more effective alternatives emerge, the demand for dendritic cell vaccines may diminish, threatening their market share. Addressing these challenges will require strategic collaborations, innovation, and sustained investment in research and development to maintain competitiveness and relevance in the dynamic oncology landscape.

Competitor Outlook

• Rpharma
• ImmunoCellular Therapeutics
• OncoOne
• Aduro Biotech
• Celgene Corporation
• GSK
• Merck & Co., Inc.
• Neon Therapeutics
• MedImmune
• Amgen
• Novartis
• Pfizer
• Seattle Genetics
• Immunomedics
• Genentech

The competitive landscape of the dendritic cell cancer vaccine market is characterized by a mix of established pharmaceutical giants and innovative biotechnology firms, all vying to capitalize on the rising demand for advanced cancer therapies. Key players are focusing on strengthening their research and development capabilities to introduce novel dendritic cell vaccine formulations that can effectively stimulate immune responses against various cancers. Major companies are increasingly investing in clinical trials to validate the safety and efficacy of their products, which is essential for gaining regulatory approvals and market penetration. Collaborations and partnerships among industry players are becoming common as they seek to leverage each other's expertise and resources to expedite the development and commercialization of dendritic cell vaccines.

Rpharma, for instance, has been at the forefront of developing dendritic cell therapies and has established strategic partnerships with leading academic institutions to advance their R&D initiatives. Their focus on personalized medicine and innovative treatment strategies has positioned them as a key player in the market. Similarly, ImmunoCellular Therapeutics is actively engaged in clinical trials targeting brain tumors with their dendritic cell vaccines, showcasing their commitment to addressing unmet medical needs and expanding treatment options for patients. Furthermore, major players like Merck & Co., Inc. and GSK are diversifying their oncology portfolios by exploring dendritic cell vaccines as part of their immunotherapy strategies, emphasizing the competitive nature of the market.

As the dendritic cell cancer vaccine market continues to evolve, companies will need to adopt agile strategies that adapt to changing market dynamics and patient needs. The landscape is expected to become increasingly competitive, with emerging players introducing innovative products and solutions. Companies that prioritize collaboration, patient-centric approaches, and robust clinical evidence will likely lead the way in shaping the future of dendritic cell cancer vaccines. Moreover, ongoing advancements in technology and a deeper understanding of cancer immunology are anticipated to spur further innovation, resulting in a vibrant and dynamic market poised for growth.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 GSK
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Amgen
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 OncoOne
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Rpharma
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Novartis
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Genentech
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 MedImmune
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Immunomedics
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Aduro Biotech
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Seattle Genetics
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Merck & Co., Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Neon Therapeutics
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Celgene Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 ImmunoCellular Therapeutics
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Dendritic Cell Cancer Vaccine Market, By Application
    • 6.1.1 Melanoma
    • 6.1.2 Prostate Cancer
    • 6.1.3 Breast Cancer
    • 6.1.4 Lung Cancer
    • 6.1.5 Others
  • 6.2 Dendritic Cell Cancer Vaccine Market, By Product Type
    • 6.2.1 Autologous Dendritic Cell Cancer Vaccine
    • 6.2.2 Allogeneic Dendritic Cell Cancer Vaccine
  • 6.3 Dendritic Cell Cancer Vaccine Market, By Ingredient Type
    • 6.3.1 Dendritic Cells
    • 6.3.2 Tumor Antigens
    • 6.3.3 Adjuvants
    • 6.3.4 Others
  • 6.4 Dendritic Cell Cancer Vaccine Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Cancer Research Centers
    • 6.4.3 Specialty Clinics
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Dendritic Cell Cancer Vaccine Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Dendritic Cell Cancer Vaccine market is categorized based on

By Product Type

• Autologous Dendritic Cell Cancer Vaccine
• Allogeneic Dendritic Cell Cancer Vaccine

By Application

• Melanoma
• Prostate Cancer
• Breast Cancer
• Lung Cancer
• Others

By Distribution Channel

• Hospitals
• Cancer Research Centers
• Specialty Clinics
• Others

By Ingredient Type

• Dendritic Cells
• Tumor Antigens
• Adjuvants
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Rpharma
• ImmunoCellular Therapeutics
• OncoOne
• Aduro Biotech
• Celgene Corporation
• GSK
• Merck & Co., Inc.
• Neon Therapeutics
• MedImmune
• Amgen
• Novartis
• Pfizer
• Seattle Genetics
• Immunomedics
• Genentech